AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2022
Sep 2, 2022
32312_dirs_2022-09-02_ae4689ea-151a-4269-a3a2-f8b6dcee1e03.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2022-08-31
Reporting Person: Belldegrun Arie (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-08-31 | Ordinary Shares | M | 3241 | $5 | Acquired | 248693 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-08-31 | Stock Option (right to buy) | $5 | M | 3241 | Disposed | 2022-09-01 | Ordinary Shares (3241) | Direct |
More from UroGen Pharma Ltd.
Annual Report
2026
May 27
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11